Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Total Current Liabilities: 2009-2024

Historic Total Current Liabilities for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $38.8 million.

  • Ironwood Pharmaceuticals' Total Current Liabilities rose 391.07% to $242.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $242.5 million, marking a year-over-year increase of 391.07%. This contributed to the annual value of $38.8 million for FY2024, which is 85.93% down from last year.
  • According to the latest figures from FY2024, Ironwood Pharmaceuticals' Total Current Liabilities is $38.8 million, which was down 85.93% from $276.1 million recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Total Current Liabilities ranged from a high of $276.1 million in FY2023 and a low of $25.5 million during FY2022.
  • Moreover, its 3-year median value for Total Current Liabilities was $38.8 million (2024), whereas its average is $113.5 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first soared by 981.69% in 2023, then slumped by 85.93% in 2024.
  • Over the past 5 years, Ironwood Pharmaceuticals' Total Current Liabilities (Yearly) stood at $32.2 million in 2020, then skyrocketed by 402.59% to $161.7 million in 2021, then tumbled by 84.21% to $25.5 million in 2022, then spiked by 981.69% to $276.1 million in 2023, then plummeted by 85.93% to $38.8 million in 2024.